Difference between revisions of "BRAF mutation"
Jump to navigation
Jump to search
| Line 2: | Line 2: | ||
==General== | ==General== | ||
*Clinical implication: BRAF inhibitors (e.g. vemurafenib) | *Clinical implication: BRAF inhibitors (e.g. vemurafenib) are used to treat BRAF mutation positive tumours.<ref name=pmid29148538>{{Cite journal | last1 = Cheng | first1 = L. | last2 = Lopez-Beltran | first2 = A. | last3 = Massari | first3 = F. | last4 = MacLennan | first4 = GT. | last5 = Montironi | first5 = R. | title = Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. | journal = Mod Pathol | volume = 31 | issue = 1 | pages = 24-38 | month = 01 | year = 2018 | doi = 10.1038/modpathol.2017.104 | PMID = 29148538 }}</ref> | ||
===Prevalence=== | ===Prevalence=== | ||
Latest revision as of 18:20, 23 January 2019
BRAF mutation is a common genetic change in cancer. The most common BRAF mutation is the so-called BRAF V600E mutation.
General
- Clinical implication: BRAF inhibitors (e.g. vemurafenib) are used to treat BRAF mutation positive tumours.[1]
Prevalence
BRAF mutations by tumour type:[1]
- BRAF mutations in ~ 50% of melanomas; respond to BRAF inhibitors.
- BRAF mutations in ~ 10% of colorectal tumours.
- Poor prognosticator, poor response to chemotherapy, typically right sided tumours.
- BRAF mutations in ~45-50% of papillary thyroid carcinoma.
- BRAF mutations in ~3% of lung adenocarcinomas.